{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T21:14:05Z","timestamp":1780607645080,"version":"3.54.1"},"reference-count":69,"publisher":"Georg Thieme Verlag KG","issue":"05","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Thromb Hemost"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Among the acquired coagulation factor deficiencies, autoimmune coagulation factor deficiencies (AiCFD) are rare and result from autoantibody production against coagulation factors. In Japan, a nationwide survey on AiCFD has been conducted since 2009. Autoimmune factor XIII, factor VIII, von Willebrand factor, factor V, and factor X deficiencies (AiF13D, AiF8D, AiVWFD, AiF5D, and AiF10D, respectively) have been enacted as \u201cdesignated intractable disease-282.\u201d The incidence of AiF8D, AiF13D, and AiF5D was 1.83, 0.044, and 0.038 per million people\/year, respectively, whereas that of AiVWFD and AiF10D was not calculable owing to the small number of patients. AiF13D and AiF8D were often idiopathic, whereas AiVWFD was often associated with plasma cell neoplasms. Epistaxis was a characteristic symptom of AiVWFD, intramuscular bleeding was frequent in AiF13D and AiF8D, and subcutaneous bleeding (purpura) was frequent in AiF13D and AiF10D, although none were specific to any one disease. Differential diagnosis cannot be made based on bleeding symptoms alone; therefore, rapid and accurate testing is mandatory. Definitive diagnosis of AiCFD necessitates identifying the presence of coagulation factor \u201cinhibitors\u201d and\/or \u201cautoantibodies.\u201d Therefore, these tests should be performed upon unexplained severe acquired coagulation factor deficiencies. The mainstay of treatment for AiCFD was hemostatic therapy and autoantibody eradication therapy, which included the replacement of coagulation factors or \u201cbypass\u201d agents and administration of immunosuppressants. The rate of hemorrhagic death was high in AiF13D (13%), followed by AiF5D (7%) and Ai10D (5%); therefore, early diagnosis and optimal treatment are essential for AiCFDs. Given the unknown long-term prognosis, \u201cintractable disease platform registries\u201d have begun to accumulate in Japan.<\/jats:p>","DOI":"10.1055\/s-0044-1787188","type":"journal-article","created":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T22:52:00Z","timestamp":1718232720000},"page":"491-505","source":"Crossref","is-referenced-by-count":14,"title":["Diagnosis and Treatment of Autoimmune Acquired Coagulation Factor Deficiencies: An Evidence-Based Review of Japanese Practice"],"prefix":"10.1055","volume":"51","author":[{"given":"Akitada","family":"Ichinose","sequence":"additional","affiliation":[{"name":"Department of Molecular Patho-Biochemistry and Patho-Biology, Yamagata University School of Medicine, Yamagata, Japan"},{"name":"The Japanese Collaborative Research Group on Autoimmune Acquired Coagulation Factor Deficiencies supported by the Japanese Ministry of Health, Labor and Welfare, Yamagata University School of Medicine, Yamagata, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsukasa","family":"Osaki","sequence":"additional","affiliation":[{"name":"Department of Molecular Patho-Biochemistry and Patho-Biology, Yamagata University School of Medicine, Yamagata, Japan"},{"name":"The Japanese Collaborative Research Group on Autoimmune Acquired Coagulation Factor Deficiencies supported by the Japanese Ministry of Health, Labor and Welfare, Yamagata University School of Medicine, Yamagata, Japan"},{"name":"Department of Public Health and Hygiene, Yamagata University Graduate School of Medical Science, Yamagata, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayoshi","family":"Souri","sequence":"additional","affiliation":[{"name":"Department of Molecular Patho-Biochemistry and Patho-Biology, Yamagata University School of Medicine, Yamagata, Japan"},{"name":"The Japanese Collaborative Research Group on Autoimmune Acquired Coagulation Factor Deficiencies supported by the Japanese Ministry of Health, Labor and Welfare, Yamagata University School of Medicine, Yamagata, Japan"},{"name":"Department of Public Health and Hygiene, Yamagata University Graduate School of Medical Science, Yamagata, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2024,6,12]]},"reference":[{"issue":"43","key":"ref1","doi-asserted-by":"crossref","first-page":"10363","DOI":"10.1021\/bi00107a001","article-title":"The coagulation cascade: initiation, maintenance, and regulation","volume":"30","author":"E W Davie","year":"1991","journal-title":"Biochemistry"},{"issue":"06","key":"ref2","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1055\/s-0037-1615947","article-title":"A cell-based model of hemostasis","volume":"85","author":"M Hoffman","year":"2001","journal-title":"Thromb Haemost"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1146\/annurev.biochem.67.1.395","article-title":"Biochemistry and genetics of von Willebrand factor","volume":"67","author":"J E Sadler","year":"1998","journal-title":"Annu Rev Biochem"},{"issue":"03","key":"ref4","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/MBC.0000000000000065","article-title":"Update on von Willebrand factor multimers: focus on high-molecular-weight multimers and their role in hemostasis","volume":"25","author":"M Stockschlaeder","year":"2014","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"07","key":"ref5","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1111\/j.1538-7836.2005.01213.x","article-title":"Factor XIII and the clotting of fibrinogen: from basic research to medicine","volume":"3","author":"L Lorand","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"04","key":"ref6","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/s12185-012-1064-3","article-title":"Factor XIII is a key molecule at the intersection of coagulation and fibrinolysis as well as inflammation and infection control","volume":"95","author":"A Ichinose","year":"2012","journal-title":"Int J Hematol"},{"issue":"04","key":"ref7","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1055\/s-0037-1614361","article-title":"Rare coagulation disorders","volume":"82","author":"F Peyvandi","year":"1999","journal-title":"Thromb Haemost"},{"issue":"05","key":"ref8","doi-asserted-by":"crossref","first-page":"405","DOI":"10.3109\/07853890.2011.576698","article-title":"Inherited disorders of blood coagulation","volume":"44","author":"G Lippi","year":"2012","journal-title":"Ann Med"},{"issue":"01","key":"ref9","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1182\/hematology.2019000066","article-title":"Management of rare acquired bleeding disorders","volume":"2019","author":"M Menegatti","year":"2019","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"issue":"03","key":"ref10","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/BF02737641","article-title":"Autoantibodies to coagulation factors and bleeding disorders","volume":"16","author":"A E Ahmed","year":"1998","journal-title":"Clin Rev Allergy Immunol"},{"issue":"05","key":"ref11","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/00062752-199909000-00009","article-title":"Acquired autoantibodies to coagulation factors","volume":"6","author":"B G Macik","year":"1999","journal-title":"Curr Opin Hematol"},{"issue":"01","key":"ref12","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.autrev.2013.08.001","article-title":"Autoantibodies to coagulation factors: from pathophysiology to diagnosis and therapy","volume":"13","author":"M Cugno","year":"2014","journal-title":"Autoimmun Rev"},{"issue":"23","key":"ref13","doi-asserted-by":"crossref","first-page":"14715","DOI":"10.3390\/ijms232314715","article-title":"Autoimmune diseases affecting hemostasis: a narrative review","volume":"23","author":"E J Favaloro","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"01","key":"ref14","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.blre.2016.08.002","article-title":"Autoimmune acquired factor XIII deficiency due to anti-factor XIII\/13 antibodies: a summary of 93 patients","volume":"31","author":"A Ichinose","year":"2017","journal-title":"Blood Rev"},{"issue":"03","key":"ref15","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1055\/a-1496-8527","article-title":"Autoimmune coagulation factor X deficiency as a rare acquired hemorrhagic disorder: a literature review","volume":"122","author":"A Ichinose","year":"2022","journal-title":"Thromb Haemost"},{"issue":"10","key":"ref16","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1007\/s00296-019-04404-7","article-title":"Lupus anticoagulant-hypoprothrombinemia syndrome and immunoglobulin-A vasculitis: a report of Japanese sibling cases and review of the literature","volume":"39","author":"K Fujiwara","year":"2019","journal-title":"Rheumatol Int"},{"issue":"02","key":"ref17","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s12185-019-02674-2","article-title":"Lupus anticoagulant-hypoprothrombinemia syndrome and similar diseases: experiences at a single center in Japan","volume":"110","author":"M Ieko","year":"2019","journal-title":"Int J Hematol"},{"issue":"05","key":"ref18","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1160\/TH10-11-0724","article-title":"As many as 12 cases with haemorrhagic acquired factor XIII deficiency due to its inhibitors were recently found in Japan","volume":"105","author":"A Ichinose","year":"2011","journal-title":"Thromb Haemost"},{"issue":"06","key":"ref19","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1055\/s-0034-1390151","article-title":"Inhibitors of Factor XIII\/13 in older patients","volume":"40","author":"A Ichinose","year":"2014","journal-title":"Semin Thromb Hemost"},{"issue":"05","key":"ref20","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/hae.12677","article-title":"Clinical features of 32 new Japanese cases with autoimmune haemorrha-philia due to anti-factor XIII antibodies","volume":"21","author":"A Ichinose","year":"2015","journal-title":"Haemophilia"},{"issue":"01","key":"ref21","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s12185-017-2210-8","article-title":"Clinical characteristics and outcomes of acquired hemophilia A: experience at a single center in Japan","volume":"106","author":"Y Ogawa","year":"2017","journal-title":"Int J Hematol"},{"issue":"02","key":"ref22","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1055\/s-0041-1740149","article-title":"A review of coagulation abnormalities of autoimmune acquired factor V deficiency with a focus on Japan","volume":"48","author":"A Ichinose","year":"2022","journal-title":"Semin Thromb Hemost"},{"issue":"05","key":"ref23","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1111\/hae.14613","article-title":"Autoimmune acquired factor XIII deficiency in Japan 2021 update: focused on annual incidence and clinical features","volume":"28","author":"A Ichinose","year":"2022","journal-title":"Haemophilia"},{"issue":"08","key":"ref24","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1055\/s-0042-1749088","article-title":"A review of autoimmune acquired von Willebrand factor deficiency in Japan","volume":"48","author":"A Ichinose","year":"2022","journal-title":"Semin Thromb Hemost"},{"issue":"04","key":"ref25","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1111\/hae.14798","article-title":"Clinical features and laboratory diagnostic issues of non-immune, non-amyloid related acquired factor X deficiency","volume":"29","author":"A Ichinose","year":"2023","journal-title":"Haemophilia"},{"issue":"02","key":"ref26","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/hae.14711","article-title":"Identification of non-neutralizing anti-factor X autoantibodies in three Japanese cases of autoimmune acquired factor X deficiency","volume":"29","author":"M Souri","year":"2023","journal-title":"Haemophilia"},{"issue":"05","key":"ref27","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1182\/blood-2006-06-029850","article-title":"Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation","volume":"109","author":"P W Collins","year":"2007","journal-title":"Blood"},{"issue":"S 03","key":"ref28","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1365-2516.2010.02259.x","article-title":"Genetic markers in acquired haemophilia","volume":"16","author":"J Oldenburg","year":"2010","journal-title":"Haemophilia"},{"issue":"09","key":"ref29","doi-asserted-by":"crossref","first-page":"e0257322","DOI":"10.1371\/journal.pone.0257322","article-title":"Important roles of the human leukocyte antigen class I and II molecules and their associated genes in the autoimmune coagulation factor XIII deficiency via whole-exome sequencing analysis","volume":"16","author":"T Osaki","year":"2021","journal-title":"PLoS One"},{"issue":"05","key":"ref30","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1007\/s12185-022-03301-3","article-title":"Plasma proteomics associated with autoimmune coagulation factor deficiencies reveals the link between inflammation and autoantibody development","volume":"115","author":"T Osaki","year":"2022","journal-title":"Int J Hematol"},{"issue":"04","key":"ref31","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/j.1538-7836.2012.04653.x","article-title":"Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders","volume":"10","author":"F Peyvandi","year":"2012","journal-title":"J Thromb Haemost"},{"issue":"03","key":"ref32","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1159\/000455938","article-title":"Successful management of a patient with autoimmune hemorrhaphilia due to anti-factor XIII\/13 antibodies complicated by pulmonary thromboembolism","volume":"137","author":"Y Ogawa","year":"2017","journal-title":"Acta Haematol"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.thromres.2022.03.006","article-title":"Retrospective examination of coagulation parameters in 33 patients with autoimmune coagulation factor deficiencies in Japan: a single-center analysis","volume":"213","author":"T Osaki","year":"2022","journal-title":"Thromb Res"},{"issue":"03","key":"ref34","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/hae.14298","article-title":"Pathological coagulation parameters in as many as 54 patients with autoimmune acquired factor XIII deficiency due to anti-factor XIII autoantibodies","volume":"27","author":"A Ichinose","year":"2021","journal-title":"Haemophilia"},{"issue":"01","key":"ref35","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s12185-011-0992-7","article-title":"Reduced difference of \u03b12-plasmin inhibitor levels between plasma and serum in patients with severe factor XIII deficiency, including autoimmune hemorrhaphilia due to anti-factor XIII antibodies","volume":"95","author":"A Ichinose","year":"2012","journal-title":"Int J Hematol"},{"key":"ref36","first-page":"535","article-title":"The effect of the difference in storage conditions on the measurement of PT","volume":"63","author":"R Masutani","year":"2014","journal-title":"Med Examination"},{"issue":"02","key":"ref37","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s12185-018-2453-z","article-title":"A discrepancy between prothrombin time and Normotest (Hepaplastintest) results is useful for diagnosis of acquired factor V inhibitors","volume":"108","author":"Y Kadohira","year":"2018","journal-title":"Int J Hematol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"286","DOI":"10.37349\/ei.2023.00103","article-title":"Considerations for simultaneous detection of autoantibodies to coagulation factor and lupus anticoagulant","volume":"3","author":"M Ieko","year":"2023","journal-title":"Explor Immunol"},{"issue":"06","key":"ref39","first-page":"667","article-title":"[Immune-mediated acquired coagulation factor deficiencies: state-of-the-art in diagnosis and management]","volume":"60","author":"A Ichinose","year":"2019","journal-title":"Rinsho Ketsueki"},{"issue":"05","key":"ref40","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/jth.12877","article-title":"Anti-factor XIII A subunit (FXIII-A) autoantibodies block FXIII-A2 B2 assembly and steal FXIII-A from native FXIII-A2 B2","volume":"13","author":"M Souri","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"06","key":"ref41","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1160\/TH14-09-0745","article-title":"Rapid immunochromatographic test for detection of anti-factor XIII A subunit antibodies can diagnose 90\u2009% of cases with autoimmune haemorrhaphilia XIII\/13","volume":"113","author":"T Osaki","year":"2015","journal-title":"Thromb Haemost"},{"issue":"08","key":"ref42","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1055\/a-2061-3182","article-title":"Novel immunochromatographic test for anti-factor XIII B subunit autoantibodies to diagnose autoimmune acquired factor XIII deficiency","volume":"123","author":"T Osaki","year":"2023","journal-title":"Thromb Haemost"},{"issue":"04","key":"ref43","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1055\/a-2002-2394","article-title":"Unmet need for reliable immunological detection method for anti-von Willebrand factor autoantibodies","volume":"123","author":"T Osaki","year":"2023","journal-title":"Thromb Haemost"},{"issue":"03","key":"ref44","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1055\/s-0038-1648872","article-title":"Antibody-induced acute factor X deficiency: clinical manifestations and properties of the antibody","volume":"72","author":"L V Rao","year":"1994","journal-title":"Thromb Haemost"},{"issue":"04","key":"ref45","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1046\/j.1365-2141.2003.04325.x","article-title":"Lupus anticoagulant associated with transient severe factor X deficiency: a report of two patients presenting with major bleeding complications","volume":"121","author":"A A Ashrani","year":"2003","journal-title":"Br J Haematol"},{"issue":"06","key":"ref46","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1097\/MBC.0b013e32835facef","article-title":"Severe inhibitor-negative acquired factor XIII\/13 deficiency with aggressive subdural haemorrhage","volume":"24","author":"H Kawano","year":"2013","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"11","key":"ref47","first-page":"2300","article-title":"[Successful treatment of chronic disseminated intravascular coagulation using recombinant human soluble thrombomodulin in a dialysis patient with dissecting aortic aneurysm]","volume":"55","author":"K Hayakawa","year":"2014","journal-title":"Rinsho Ketsueki"},{"issue":"02","key":"ref48","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1046\/j.1365-2141.2000.02183.x","article-title":"Bleeding symptoms and coagulation abnormalities in 337 patients with AL-amyloidosis","volume":"110","author":"A D Mumford","year":"2000","journal-title":"Br J Haematol"},{"issue":"06","key":"ref49","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1182\/blood.V97.6.1885","article-title":"Acquired factor X deficiency in patients with amyloid light-chain amyloidosis: incidence, bleeding manifestations, and response to high-dose chemotherapy","volume":"97","author":"E B Choufani","year":"2001","journal-title":"Blood"},{"issue":"05","key":"ref50","doi-asserted-by":"crossref","first-page":"e350","DOI":"10.1111\/hae.13843","article-title":"The first reported case of acquired haemophilia A in which bleeding episodes were successfully treated via administration of a single-dose mixture of activated factor VIIa\/X","volume":"25","author":"S Yamada","year":"2019","journal-title":"Haemophilia"},{"issue":"02","key":"ref51","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/hae.14710","article-title":"Plasma-derived factor VIIa and factor X mixture agent (MC710) prophylaxis in haemophilia B patients with inhibitors","volume":"29","author":"M Sakai","year":"2023","journal-title":"Haemophilia"},{"issue":"04","key":"ref52","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1111\/jth.14746","article-title":"An anti-factor IXa\/factor X bispecific antibody, emicizumab, improves ex vivo coagulant potentials in plasma from patients with acquired hemophilia A","volume":"18","author":"M Takeyama","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"01","key":"ref53","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1182\/blood.V60.1.59.59","article-title":"Radioimmunoassay of factor V in human plasma and platelets","volume":"60","author":"P B Tracy","year":"1982","journal-title":"Blood"},{"issue":"06","key":"ref54","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s12185-020-02837-6","article-title":"Plasma-derived factors VIIa and X mixtures (Byclot\u00ae) significantly improve impairment of coagulant potential ex vivo in plasmas from acquired hemophilia A patients","volume":"111","author":"S Ochi","year":"2020","journal-title":"Int J Hematol"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/0091-6749(89)90193-0","article-title":"Modulation of Fc receptor clearance and antiplatelet antibodies as a consequence of intravenous immune globulin infusion in patients with immune thrombocytopenic purpura","volume":"84","author":"J B Bussel","year":"1989","journal-title":"J Allergy Clin Immunol"},{"issue":"04","key":"ref56","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.humimm.2005.01.031","article-title":"Use of intravenous immunoglobulin in patients with acquired von Willebrand syndrome","volume":"66","author":"A B Federici","year":"2005","journal-title":"Hum Immunol"},{"issue":"12","key":"ref57","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1111\/jth.15515","article-title":"Predictive significance of anti-FVIII immunoglobulin patterns on bleeding phenotype and outcomes in acquired hemophilia A: results from the Quebec Reference Center for Inhibitors","volume":"19","author":"A Bonnefoy","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"06","key":"ref58","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0049-3848(01)00385-1","article-title":"Immunological characterization of factor VIII autoantibodies in patients with acquired hemophilia A in the presence or absence of underlying disease","volume":"104","author":"T Matsumoto","year":"2001","journal-title":"Thromb Res"},{"issue":"01","key":"ref59","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s12185-017-2273-6","article-title":"First report of real-time monitoring of coagulation function potential and IgG subtype of anti-FVIII autoantibodies in a child with acquired hemophilia A associated with streptococcal infection and amoxicillin","volume":"107","author":"M Takeyama","year":"2018","journal-title":"Int J Hematol"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"140","DOI":"10.2491\/jjsth.19.140","article-title":"A 3-year consecutive survey on current status of acquired inhibitors against coagulation factors in Japan\u2014analysis of prognostic factors","volume":"19","author":"I Tanaka","year":"2008","journal-title":"Japan J Thromb Haemost"},{"issue":"02","key":"ref61","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jtha.2022.11.019","article-title":"Cloning of human anti-factor XIII monoclonal antibody dissects mechanisms of polyclonal antibodies in a single patient","volume":"21","author":"M Souri","year":"2023","journal-title":"J Thromb Haemost"},{"issue":"09","key":"ref62","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1002\/1873-3468.14606","article-title":"Epitope analysis of human monoclonal antibodies from a patient with autoimmune factor XIII deficiency reveals their inhibitory mechanisms","volume":"597","author":"T Osaki","year":"2023","journal-title":"FEBS Lett"},{"issue":"01","key":"ref63","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s12185-021-03212-9","article-title":"Measurement of coagulation factor antibody levels is useful for diagnosis and determining therapeutic efficacy in hemorrhagic patients with autoantibodies to coagulation factor VIII and factor V: results from a single center in Japan","volume":"115","author":"M Ieko","year":"2022","journal-title":"Int J Hematol"},{"issue":"11","key":"ref64","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1111\/j.1538-7836.2010.04028.x","article-title":"Factor XIII\u2013an under diagnosed deficiency\u2013are we using the right assays?","volume":"8","author":"A S Lawrie","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"03","key":"ref65","first-page":"271","article-title":"A chromogenic substrate method for detecting and titrating anti-factor VIII antibodies in the presence of lupus anticoagulant","volume":"87","author":"A N Blanco","year":"2002","journal-title":"Haematologica"},{"issue":"05","key":"ref66","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/ijlh.13083","article-title":"Performance evaluation of Revohem\u2122 FVIII chromogenic and Revohem\u2122 FIX chromogenic in the CS-5100 autoanalyser","volume":"41","author":"A Suzuki","year":"2019","journal-title":"Int J Lab Hematol"},{"issue":"03","key":"ref67","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1055\/s-0038-1624581","article-title":"Recombinant FXIII (rFXIII-A2) prophylaxis prevents bleeding and allows for surgery in patients with congenital FXIII A-subunit deficiency","volume":"118","author":"M Carcao","year":"2018","journal-title":"Thromb Haemost"},{"issue":"17","key":"ref68","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood-2015-02-629873","article-title":"Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease","volume":"126","author":"J C Gill","year":"2015","journal-title":"Blood"},{"key":"ref69","first-page":"27","article-title":"Autoimmune acquired coagulation factor deficiencies (designated intractable disease-288)","volume":"11","author":"A Ichinose","year":"2021","journal-title":"Thromb Med"}],"container-title":["Seminars in Thrombosis and Hemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0044-1787188.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T23:50:40Z","timestamp":1750204240000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0044-1787188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,12]]},"references-count":69,"journal-issue":{"issue":"05","published-online":{"date-parts":[[2025,6,13]]},"published-print":{"date-parts":[[2025,7]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0044-1787188","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0094-6176","1098-9064"],"issn-type":[{"value":"0094-6176","type":"print"},{"value":"1098-9064","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,12]]}}}